Legend Biotech Corporation

Good day and welcome to the Legend Biotech fourth quarter and full year 2024 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Instructions will be given at that time. As a reminder, this call may be recorded. I would like to turn the call over to Caroline Paul, Associate Director of Investor Relations. Please go ahead.

Good morning. Good morning. This is Caroline Paul, Associate Director of Investor Relations at Legend Biotech. Thank you for joining our conference call today to review our fourth quarter of 2024 performance. Prior to this call, we issued a press release announcing our financial results for the quarter. You can find the press release on our IR website at legendbiotech.com. Joining me on today's call are Ying Kuang, the company's Chief Executive Officer, and Jesse Young, the company's interim chief financial officer. Following the prepared remarks, we will open up the call for Q&A. We have our president of Carbectie, Alan Bash, president of R&D, Goi Fang, and chief medical officer, Maithili Konaru, joining the Q&A session. During today's call, we will be making forward-looking statements which are subject to risks and uncertainties that may cause our actual results to differ materially from those expressed or implied here within. These forward-looking statements are discussed in greater detail in our SEC filings, which we encourage you to read and can be found under the Investors section of our company website. In addition, adjusted net loss is a non-IFRS metric. This non-IFRS financial measure is in addition to and not a substitute for or superior to measures of financial performance prepared in accordance with IFRS. There are a number of limitations related to the use of these non-IFRS financial measures versus their closest IFRS equivalents. However, we believe that providing information concerning adjusted net loss and adjusted net loss per share enhances an investor's understanding of our financial performance. We use adjusted net loss as a performance metric that guides management in its operation of and planning for the future of the business. We believe that adjusted net loss provides a useful measure of our operating performance from period to period by excluding certain items that we believe are not representative of our core business. Our press release includes IFRS to non-IFRS reconciliations for these measures. With that, I will now turn the call over to Yang.

Hello, everyone. I am glad that you are able to join us and hear about our recent accomplishments as the largest standalone cell therapy company. As you can see on slide 6, we have been executing against our strategic priorities, paving the way for us to achieve blockbuster status and operational break-even for Carvicti by the end of 2025, and anticipated company-wide profitability in 2026, excluding unrealized foreign exchange gains or losses. I would like to start by expanding on CARVICTI's unique profile, which is the first and only CAR-T in multiple myeloma to clinically demonstrate a survival benefit versus standard of care. At the ASH 2024 annual meeting, we shared new results from the Phase III CARTITUDE IV study that show 89% of invaluable patients achieved minimal residual disease negativity with a single infusion of CARVICTI after a three-year follow-up compared to 38% for those treated with standard of care. As you may know, the FDA ODAC Committee recently recommended the uses of MRG negativity as discretion as a potential surrogate endpoint in multiple myeloma trials, which creates other potential opportunities for approval in the future. Additionally, we're pleased to see that CARVICT outcomes data is reaching the broader multiple myeloma community. The International Myeloma Working Group recently published a series of core recommendations on sequencing therapy for the treatment of multiple myeloma. Notably, one of these recommendations in patients who are reasonable candidates for both BCMA CAR T therapy and bispecific T cell engagers is to pursue CAR T therapy first. Our sales trajectory since our launch is no doubt due to Carvicti's unique profile, along with strong manufacturing and commercial execution. Remember, Legend and J&J are pioneering and undertaking at a scale that we believe has never been done before in the field of multiple myeloma for CAR-T. On this note, on slide seven, we'd like to highlight how the FDA has approved our CMO Novartis facility for commercial production of Carvicti in New Jersey. We are looking forward to initiating clinical production at our facility called TechLand in Ghent, Belgium in the coming weeks and initiating commercial production there later this year. This is another critical component of our plans for serving patients in Europe and beyond to meet the increasing demand. We are thrilled with our industry-leading early launch performance and we're not stopping there. We continue our commitment to bringing Carvicti to all eligible patients in the U.S. and Europe who might benefit from its differentiated efficacy. We're pleased that Carvicti recently received approval for reimbursement in Spain. Moving to slide 9, in the fourth quarter of 2024, net trade sales of Carvicti were approximately $334 million. which is a 110% increase year-over-year and a 17% increase from third quarter. This performance was aligned with our expectation for accelerating growth in the second half of last year and was driven by strong demand, continued capacity expansion, and the Carditude 4 label launch for use as early as the second line. Regarding OUS performance, sales of $31 million increased 138% year-over-year, and 15% quarter over quarter, owing to our recent increases in capacity and launches in Germany, Austria, Switzerland, and Brazil. In the United States, we continue to certify more hospitals as authorized treatment centers. The total number of US hospitals that are certified to treat with CARVICTI is now 102. We believe outpatient administration remains another key competitive advantage for us. CARVICTI is the only approved CAR T in multiple myeloma that has seen significant use in outpatient settings. Because of the delayed onset of CRS with CARVICTI, providers are able to utilize outpatient administration to support patient needs. We are pleased with the progress we have made since one year ago when outpatient treatment accounted for 30% of our overall volume. and anticipate a majority of our volume coming from outpatient use by end of this year. We're also committed to facilitating best practice sharing as we treat more and more patients. We have now treated over 5,000 patients with CAR-VT, which has created the most comprehensive CAR-T patient data set in multiple myeloma. New data is constantly being generated about CARVICTI's benefit over risk profile. For example, at the tender meeting in February, as you can see on slide 10, real-world data was presented on risk mitigation strategies for CARVICTI. On the clinical front for CARVICTI, as you may know, CARVICTI 5 is fully enrolled, and we expect to complete enrollment for CARVICTI 6 this year. We believe these trials are key to moving CARVICTI into the frontline setting. We believe these studies we have underway and our manufacturing and commercial execution will enable us to maximize Carvicti's potential. As you can see on slide 12, Carvicti is the proven leader forging the path to cure in multiple myeloma. Turning to our upcoming company milestones on slide 14, as we continue to work toward doubling Carvicti's supply in 2025, we anticipate growth to be driven by capacity expansion in Belgium and in New Jersey In addition to increasing our manufacturing capacity, we're working to include our overall survival benefit in CARVICTI's label, which is the gold standard that doctors want for their patients. Looking at long-term growth for legend, we're building out our pipeline programs, and we look to use the successful model we have pioneered with CARVICTI and take it to other therapeutic areas where options are limited. These include blood cancers and next-generation multiple myeloma therapies. solid tumor programs, and autoimmune diseases. The new research facility we're building in Philadelphia is a testament to our commitment to pipeline investments, and we are looking forward to opening it later this year. To sum up, Carvicti is the market leader in multiple myeloma CAR T therapies. We have scaled up our business and delivered on our commitment to doubling Carvicti's supply. We have continued to expand the body of evidence on CARB-X's differentiated clinical profile, and we continue to build out our pipeline to leverage our end-to-end expertise and ensure long-term growth. Now it's time to take a closer look at the financials, so I'll turn that call over to Jessie.

Thank you, Ying, and good morning, everyone. As Ying mentioned, we generated approximately $334 million in total net sales for Cavite during the fourth quarter, an increase of 110% year-over-year. As a reminder, we share equally in all profits and losses of Cavite with our partner, Jensen. As you can see on slide 15, total revenues for the fourth quarter were $187 million in consisting of $168 million of collaboration revenue from the sale of coffee tea and license revenue of $18 million from the recognition of deferred revenue in connection with our license agreement with Novartis for the development, manufacture, and commercialization of LB2102 and other CAR-T therapies selectively targeting DLF3. Net profit for the fourth quarter was $26 million, or $0.07 per share, compared to net loss of $145 million, or $0.40 per share, for the same period. The increase was primarily driven by an unrealized foreign exchange gain of $110 million for the quarter due to our Treasury Center base in Ireland. We have U.S. dollar-denominated deposits. while the functional currency in Ireland is Euro. For the same period last year, $38 million in unrealized foreign exchange loss was reported. As we have said in past quarters, largest fluctuation in unrealized gains and losses can occur from quarter to quarter due to our treasury center base in Ireland. Moving on to expenses. Collaboration cost of revenue for the fourth quarter 2024 was $69 million, compared to $32 million for the same period last year. These expenses are Legend's portion of collaboration costs of sales in connection with collaboration revenue under the Jensen's agreement, along with expenditure to support the manufacturing capacity expansion. Additionally, cost of license and other revenue for the fourth quarter of 2024 was $5 million, compared to no cost of license and other revenue for the fourth quarter of 2023. These costs are in connection with our license agreement with Novartis for the development, manufacture, and commercialization of LB2102 and other potential cardiotherapy selectively targeting DLL3. Research and development expenses remain flattish for the fourth quarter 2024 at $104 million, compared to $106 million for the same period last year, as we continue to develop CiltaCell and our pipeline programs, such as our Solituma programs. Administrative expenses for the fourth quarter were $34 million, compared to $29 million for the same period last year. The increase of $5 million year over year is primarily due to the expansion of administrative functions and infrastructures to increase manufacturing capacity. Selling and distribution expense for the fourth quarter was $49 million compared to $34 million for the same period last year. the increase of $15 million year-over-year was due to costs associated with the commercial activities for Kavikti, including the expansion of the sales force and second-line intercation launch. Other incomes were $125 million for the fourth quarter compared to $18 million for the same period last year. The increase was almost entirely driven by an unrealized foreign exchange gain for the three months ended December 31, 2024, In the same period last year, there was an unrealized foreign exchange loss of $38 million. The unrealized foreign exchange gains and losses were primarily driven by our treasury center base in Ireland. We have U.S. dollar denominated deposits, while the functional currency in Ireland is euro. On this note, on slide 18, you'll notice we are introducing non-IFRS earnings measures to provide more insights into our financial performance. After excluding certain items that are not representative of the company's core business, our adjusted net loss of $59 million or $0.16 per share for the fourth quarter compared to an adjusted net loss of $89 million or $0.24 per share for the same period. Finally, we ended the year with $1.1 billion in cash and equivalents and time deposits. Our spending remains on track and we continue to maintain a strong balance sheet. Thus, we believe we have sufficient capital to fund our operating and capital expenditures until we anticipate reaching profitability in 2026, excluding unrealized forward exchange gains or losses. Our profitability guidance implies further growth acceleration, which shows that we are making good progress towards our long-term goals. I will now pass it back to Ying for closing remarks.

Thank you, Jesse.

Carvicti is the fastest-launched CAR T therapy. The achievements of our global teams have set us up for great success in 2025, and we are poised to provide Carvicti to even more patients around the world. I want to thank each of our 2,600 employees for their commitment and dedication to a legend. Now it's time to take your questions. Operator, we're ready for the first question, please.

Thank you. If you'd like to ask a question, please press star 1-1. If your question has been answered and you'd like to remove yourself from the queue, please press star 11 again. Our first question comes from John Miller with Evercore. Your line is open.

Hi, guys. Thanks for taking my question, and congrats on all of the progress and a great fourth quarter. I would love to ask more about the safety profile and your plans to developing a trial that more aggressively manages ICANNs and Neurotox in a more trial-like setting. I think we all saw the IST posters that came out a month ago. That's great. But, Ying, you've spoken in the past to running your own Phase II using a more Arcelics-like management system. Where are the plans for that trial, and when is the earliest we can see data from that? Thank you.

Sure, thank you for your question. So, regarding the posters that were presented at Tandem, these were single center studies, but I think they represent a promising start to the risk mitigation strategies we've discussed recently using absolute lymphocyte count, or ALC, as a predictive biomarker for patients who are at higher risk for MNTs or Parkinsonism. In those posters, CBCI chose that threshold of 5,000 whereas Mayo Clinic actually used the threshold of 3,000 as a predictive cutoff. I think our CARTITUDE studies or internal programs indicate that it's actually probably more consistent with 3,000 to try to capture as many of these patients as possible. We actually had a discussion with the investigators at CBCI, and they're planning on moving forward with the 3,000 as a cutoff for future investigation. But regardless of the cutoff, I think it's clear that ALC is a predictive biomarker and when used in conjunction with the dexamethasone treatment with the goal of decreasing or potentially preventing Parkinsonism altogether. So, going forward, I think we've harmonized these ALC cutoffs within the CARTICUDE studies and have ongoing enrollment as the year continues. It's also important to mention the prospective study that you're referring to, which will be an investigator initiated trial by some of these investigators that presented their information at tandem. I think with the conjunction of the internal efforts, as well as the external efforts with the. investigator-initiated trial using the cutoff that I just mentioned. I think we'll have some data that will be presented throughout this year as well as into next year that will address the MNTs and the Parkinsonism. The poster also, the Mayo Clinic mentioned the cranial nerve palsies. I think it's important to highlight that cranial nerve palsies tend to be reversible in a majority of cases. In fact, the two cases that presented the cranial palsy from the CBCI actually showed complete resolution of their symptoms using the prednisone taper as well as the satinib for seven days. And in general, as I mentioned, the cranial palsy tend to be irreversible. The ICANNs and MNTs are the most notable, but we have clear mitigation strategies for these going forward and we're confident in the benefit-risk profile that is overall positive for CARB-ICT.

Thanks, Mai. And then, Joe, maybe I'll just add a comment about our own sponsor trials. So, we have already amended all the protocols for the CART2 program, including ongoing CART2-6 and also ongoing CART2-2, including additional new cohorts for CART2-2. So that will be with a cutoff of 3,000 cells per microliter for ALC monitoring, and then a three-day flat dosing of 10 milligrams twice daily for three days. So that's already being implemented at all the CART2 program sites.

Excellent. Thanks so much. If I could get one follow-up, I'm very curious to hear about your plans for ASCO this year. Are you going to have meaningful updates to your existing trials and new data in early lines this year?

So, John, as you know, the typical policy for both J&J and Legends disclosure plus is that we cannot comment until the abstract is officially accepted by any major medical meeting. But suffice to say that, you know, both Legends and J&J are very excited about the data we're presenting at ASCO potentially this year. So stay tuned.

Thanks so much.

Thank you. Our next question comes from Gina Wang with Barclays. Your line is open.

Hi, thanks for taking our question. This is Hangu on behalf of Gina Wang. So our questions are about commercial. So first one is that, like, what's the quarterly revenue breakdown in terms of the second-line to third-line patients versus four-plus-line patients? And the second one is, what's your response to the demand for cardiotherapy in multiple myeloma we see it is higher than the numbers of patients receiving treatment now. So could you give more colors on that? For instance, what's kind of like the physician capacity and also for the additional patients could be treated with CAR T therapy, whether they're from the academic center?

Yeah, thanks.

Thanks for the question.

So, with respect to market demand and commercial uptake, we continue to get good receptivity to the CARTITUDE 4 data. And I'll just share a little bit more about what we're hearing from customers and then go into some of the numbers. We're hearing very positive receptivity to the clinical profile, inclusive of obviously the PFS and the overall survival data that's now in the public domain, all from a one-time treatment. And as you mentioned, Uh, indication in earlier lines, specifically the, the 2nd through 4th line opportunity. And at this point, we're about 3 quarters plus into the launch of the cartitude for indication. And we have already converted nearly 60% of our usage to that of in the 2nd through 4th line population. So that's a very strong evolution quarter on quarter. Uh, of bringing our, our, our total revenue across to earlier lines. And it sets up well. to maintain leadership in these earlier line opportunities.

Thank you, Alan. And I will also add that, you know, both our commercial field forces and also from our partner, J&J, are now targeting 8,000 hematologists in about 3,000 clinics. So, we're working very hard to penetrate deeply into the community setting.

Thanks so much for the answers. Appreciate that.

Thank you. Our next question comes from Yaron Werber with TD Cowan. Your line is open.

Great. Thanks for taking my question. Maybe a couple. The first one is just housekeeping. The share count, I noticed that you're using the fully diluted 402, which is up from 367 last quarter. Is this the run rate we should use from now on, or is there kind of a one-timer in there or anti-dilution kind of measures, and that's why you're using that? And then the second one is more about the pipeline. Can you give us a sense, what data can we expect from sort of the early pipeline and maybe some of the I&I programs that you have going on and anything this year? Thank you.

Hi, everyone. So for this time, we actually recorded a net profit with the IFRS measures. And then with net profit, we have to calculate using all the investor share as well. So you see a different number of other diluted numbers. But going forward, if we switch back to net loss, then you will see the same calculation as before again.

So for the early pipeline, we are very excited about a few key categories this year. We have two U.S. Phase I programs, Autogest, such as the targeting card 18.4 for gastric as well as targeting DL3 for small cell lung cancer. We will have the dose excretion readout this year and then decide to the next phase of development. On the IHG tri-site from China, we have multiple readout on allogeneic program targeting different diseases. We expect to have those readout before end of this year as well. As Ian communicated, we are just about to initiate a new research center at Philadelphia, focusing on disruptive technology, including the in-view of cell therapy approach. We expect to see ASET moving into clinic development with that particular platform. Lastly, I think on the autoimmune front, we have multiple programs currently undergoing IAT trials, including both autologous as well as allogeneic approach. In particular, we have a triple targeting autologous cell therapy product, targeting CD19, CD20, CD22. And this asset is being tested across a very broad spectrum of autoimmune diseases. In fact, more than 10 different disease indications. We expect to have an initial clinical readout for this particular asset as well.

Thank you. Our next question comes from Jessica Fai with JPMorgan. Your line is open.

Hey, guys. Good morning. Thanks for taking our question. With all the various sources of capacity, slots, et cetera, kind of coming online, can you just give us a little color about how to think about the cadence of revenue growth this year? Thank you.

Yeah, so overall, we're feeling reasonably confident about doubling capacity and achieving the consensus number. And as our partner, J&J, has said previously, and as we'll share a little bit more here, our growth over 2025 will not be perfectly linear. So just the way to think about it is coming off of a strong Q4 in the back half of 2024. We anticipate Q1 that's more modest growth compared to the Q4, and that's really because of seasonality and the fact that in November and December during the holiday weeks, we took the opportunity to do some important and regulatory required facility maintenance. So that will actually lag into revenue in Q1. Following that, we expect step-ups in our manufacturing due to the Raritan step-up. as well as the approval of the Novartis commercial operations. And so that will have a more meaningful impact in Q2 and Q3 as we see more meaningful growth in those two quarters.

Thank you.

Thank you. Our next question comes from Ziyi Chen with Goldman Sachs. Your line is open.

Hey, thank you for taking my questions. Um, well, since you mentioned about our stage pipelines, including the all three, and it called the 18.2 80 car T, I'm kind of wondering. Could you share more color on the expected data for both assets this year and also the future clinical development strategies? And I'm trying to understand what is your perspective on the positioning for CAR T therapies and solid tumor treatment? And based on the data you have seen, you know, if there are any obstacles you have been seeing in solid tumor CAR T development? Thank you.

Thank you for your question. So, as Go Wei mentioned earlier, both DLL3 in the cloud and 18.2 CAR T, are currently in dose escalation. We actually are making good progress on both studies and we look forward to presenting the safety dose escalation data and some preliminary efficacy this year at multiple different conferences. Safety preliminary efficacy as well as actually biomarker data that's actually quite interesting for both programs. I think deal three, we hope to complete the dose escalation and the entirety of twenty patients as planned. As you probably know, this study is under a collaboration with Novartis. And so they are looking to continue the development of this and it's clear that. This construct is of particular interest, and as you'll see throughout this year, really exciting data will be discussed in various venues. Regarding the Clouden 18.2, similarly, we are planning to complete the dose escalation this year and begin dose expansions. Currently, Clouden 18.2 is an appropriate target in pancreatic cancer and gastric cancer, among others. So, we look forward to presenting, again, the safety as well as biomarker data and starting the expansions probably in the second half of this year.

Yeah, I can also add a bit more color in terms of our overall early pipeline strategy for solid tumor. There are certain disease indication where a medical need is tremendous, such as pancreatic cancer and small cell lung cancer. A good advocacy at with manageable safety profile would have a commercial pass forward. We are seeing other disease indication. Probably additional new innovation is required to really drive a commercial success of self therapy in solid tumor space. So, in those indication, we are really continued to innovate in different directions. For example, trying to improve the. duration of response by engineering more complex cell therapy products, reconstituting both the innate as well as the adaptive immunity, and engineering various immune mechanisms to promote the immune product infiltration into tumor microenvironment, et cetera. So stay tuned, and we will have more additional innovation in the solid tumor space.

Thank you so much, Dr. Fong. Looking forward to that.

Thank you. Our next question comes from Kelly Shi with Jefferies. Your line is open.

Hi, thanks for taking my question. This is the housing for calling for Kelly Shi. I just have one quick question. We know that two BCMA bispecifics are expected to report second to fourth line data in 2025 from J&J and Pfizer. And both trials excluded patients with prior BCMA agents. So my question is, how do you see bispecifics competing with CARV-T in general? And as you mentioned, that IMWG recommended using CAR-T ahead of bispecifics based on existing data. What could we learn from this new upcoming data from those two bispecifics? Thank you.

As you mentioned, the BCMA bispecifics do exclude prior BCMA agents, and they're approved in later lines of therapy compared to the current approval for CAR-VICT in second line and beyond. Therefore, you know, IMG and WG, as you mentioned, in patients who are candidates for both, do recommend CAR-T based on its superior efficacy. And overall benefit to risk profile in general, we do plan to continue to penetrate into these earlier lines of therapy as Alan has mentioned. And so we hope to also continue not only in the academic centers, but also in the community setting. So we hope to continue to show this by our sales and growth for.

And thanks, my conference. Maybe I'll add a couple points about this. I think both treatment modalities will have its place in the market. On the other hand, I do want to emphasize some of the unmatched benefits offered by CAR-T, especially CAR-VT. First of all, as you can see from both late line and now second line data that CAR-VT offers unmatched depth and durability of response in even late line patients in Cardio 2.1, we demonstrated a median PFS of nearly three years. And so far, the median PFS has not been reached yet in the second line of Cardio 2.4. And secondly, I think, which is probably underappreciated by investors, but when we talk to physicians and customers such as end-user patients, they do appreciate the fact that CARVICTI offers the convenience of one-time treatment. And that offers patients a very long treatment-free period. which translates into improved quality of life. So I think that's another significant benefit offered by CAR T therapy.

Thank you.

Thank you. Our next question comes from Leonid Timoshev with RBC Capital Markets. Your line is open.

Hey, guys. Thanks for taking my question. I want to follow up on Jessica's question, but maybe it was a bit longer of a time horizon. You guys have talked about exiting 2025 with at least 10,000 doses, and I guess historically people have been assigning what they think that might be in revenues, but consensus for 2026 is well below what people have historically thought that number could be. What do you think the street is missing about 2026? Are you going to be able to utilize the full 10,000 doses in 2026? Is 2026 sort of a point where you're no longer going to be supply caps? How should we think about sort of that time period and beyond? Thanks.

Yeah, hi.

So, as we exit 2025 with 10,000, that's an annualized number, so that's an annualized run rate. So, as we think about 2026, We will be in a position to supply the market. And, you know, we're seeing very good evolution of our shares as well as our uptake in the community. We're really just at the very beginning of what we think Curvicti can achieve relative to, you know, here we're in 102 centers. Actually, now we're up to 104 certified sites as of today. we continue to expect that the number of sites will expand significantly. As Ying mentioned, we're also now have a very significant presence in the community and our partner, J&J, is very much a leader in the community setting. So by reaching all of those referrals and then ultimately having CARVIC-D administered even closer to the patient in more centers and into the community setting, we expect that there's significant upside there. You know, from a manufacturing standpoint, we're very comfortable with the supply network that we've built across the four nodes. So, as mentioned, Raritan will continue to have step-ups and then a physical plant expansion in the second half of this year. Novartis is coming online right as we speak. We also have the two facilities in Europe to support the European launches. both the obelisk facility is at capacity and continuing to deliver, as well as by the end of 2025, that's when we'll have our tech lane facility. And those will be supporting our ex-U.S. markets, and that will continue to be a meaningful contributor to our top line. Right now, ex-U.S. is about 10% of our revenue, but we continue to see that that will grow. Germany, the demand is strong, and we have the additional European markets. And as was mentioned today, Spain now has national reimbursement. So, And as you know, J&J is our partner in Europe, and they take the lead on commercialization, but we're very comfortable with the fact that there's going to be continued demand from Europe as well.

Thank you, Alan. And Leo, maybe I'll just add a couple points here. Number one, you heard from Alan that we're very pleased recently Novartis did receive the FDA approval for commercial production in the U.S., and also we did receive the spend reimbursement pricing. Lastly, I also want to emphasize another fact, which is that based on our internal projection for the demand, Legend and J&J have decided to jointly invest in expansion of Techland facility. So that has received the executive committee from J&J's approval and also Legend's board of director approval. And we should expect additional capacity coming online in 2028 from our Techland facility in Belgium. That shows you that both partners are very confident about the demand.

Thank you. Our next question comes from Vikram Parowit with Morgan Stanley. Your line is open.

Hi, good morning. Thanks for taking your question. We just wanted to revisit the topic of expanded use for CAR-VICT in the community setting. You spoke about this a little bit, but I was wondering if you could unpack in a bit more detail what some of the key inflection points are that you're looking for throughout the course of this year to ensure that uptake in the community setting is, in the Second Line Plus setting, is trending how you would want it to trend. And also, as you go through the year, what you will be looking to learn to better understand how, I guess, first-line uptake potentially could look for CARB-ICT, assuming those trials are successful in the community setting as well. Thank you.

Yeah, so as it relates to adoption in the community, we look at it in terms of a three-stage plan, and right now we're in the first stage, which is to educate community physicians. As Ying mentioned, we are reaching over 8,000 community oncologists who treat myeloma, educating them on the profile and supporting them as they refer patients into the certified treatment centers. And that's going very well, and every day we're out there, we're getting more support for referring those patients, and the IMWG recommendation around considering referral for CAR-T is supportive of that. We're also building connections between the treaters in the certified treatment centers and the referrers so that the referrers know where and how to send patients. The second stage will be, as we initiate this later this year, will be to identify certain regional hospitals and community accounts who are closely affiliated with hospitals who can actually go ahead and administer CAR-VICTI on site. And I'll speak about outpatient in a moment. But then the third stage is really bringing CURVIC-D even closer to the patient and having it more widely administered in the community oncology practices. We expect that to be an effort that will really begin in earnest next year and carry us through kind of the next few years as CURVIC-D gets administered into the community setting. As mentioned, we're obviously partnered with the leader in myeloma in J&J. They have outstanding capabilities. In terms of reimbursement and access and commercial footprint and both companies are now deploying commercial sales field medical nurse educators in the community in terms of outpatient just to share a little bit about that. We currently see that a little over half of our business right now. is administered in the outpatient setting. That's really driven by the fact that we have a unique profile. Our median onset of CRS, as you know, is seven days. And so that enables patients to be more comfortably administered in the outpatient setting and then monitored more locally. And that's a better experience for patients. And importantly, it expands the capacity for the treatment centers because they don't have to use inpatient beds. for the administration of CARVEcD, and that's a unique aspect of our profile that is gaining good receptivity both at the treatment centers we're in as well as in the community.

Thank you. Our next question comes from Costas Biliris with BMO Capital Markets. Your line is open.

Thanks for taking our question and congrats on the progress. Two quick questions from us, one on the activated centers. You mentioned there are currently 102 activated centers. Can you break this number down to how many of these centers can do both outpatient and inpatient administration, only outpatient or only inpatient? And the second question is on Currently ongoing clinical trials with in vivo CAR T therapies in multiple myeloma. How are you thinking about competition from in vivo CAR T products, given the convenience that they could potentially offer? Thank you.

Yes, so as we put on the slide deck, 102 centers in the U.S. have been activated, and actually as of today, that number is 104, so we continue to add centers each day, and I should mention that across globally, across Europe, there are another 40 or so centers activated. But just to answer your second part, while we don't break it down specifically center by center, we can say that the majority of patients are receiving curvectin in the outpatient setting. We look at that through claims data, and we have a number of other sources. So again, a little over half of the patients right now are being administered in the outpatient setting. Newer centers, just to just add one more point, as we bring centers on, newer centers sometimes start in the inpatient until they get a little bit more experience, and then they gain the comfort to start it in outpatient. So as we bring new centers on, sometimes it's a start in the inpatient, but they very quickly realize that they, based on the profile and based on the logistics and based on their capacity, they're able to implement an outpatient protocol.

Yeah, so on the renewable front, we are closely monitoring and paying attention. It's a new technology, certainly bringing a potential advantage and also potential liability. It's in early days, and so far, one patient data was released by a tech company, and we are closely monitoring safety as well as the durability of the response. On the in vivo front, we also have our own differentiated platform, and we are actively pursuing the in vivo treatment option for various diseases as well.

Thank you. Our next question comes from Mitchell Kapoor with HC Wainwright. Your line is open.

Hey, everyone. Thanks for taking the questions. First one is I wanted to ask if you could give an update on your demand relative to supply. When do you expect that all supply constraints could be potentially alleviated for supply to be able to outpace demand? And then secondly, could you just talk about demand increasing on a per-center basis? Is this, you know, on a per-center basis, are you seeing more demand there, or is it coming from more centers coming online generally?

You know, as we've said before, we're executing well on both the demand and supply, and really by the end of this year, we'll be in a situation where supply is fully meeting the demand where we are, and then we'll be able to keep pace with that. To answer your question, we don't break it down in terms of specific sources, but I'll just share a little bit on that. The predominant growth will be coming from the existing centers and the referral base into those centers. And so, as I mentioned before, as we reach out into the community and as we educate on the earlier line approval for CARVICTI, the main source of growth will be in those referrals coming into the 104 acclimated centers.

Great. Thank you very much.

Thank you. Our next question comes from James Shin with DB. Your line is open.

Hey, morning, guys. Thanks for the question. Are there any updates on removing fact accreditation to broaden out outpatient CART2 use? And then secondly, given CART2 5 and 6 protocols now include ALC, have you decided whether there will be a breakout for those that reach 3,000 cells per ml requiring intervention versus those that do not?

In terms of fact accreditation, the plan that we've heard from some centers is to really do more of an affiliation where they can be part of a fact accreditation umbrella from a larger institution. Rather than removing wholesale, it's more about leveraging the fact accreditation from a larger center.

I think regarding your ALC question, I think we just want to clarify that the ALC mitigation strategy was only incorporated into studies that are ongoing enrollment. So, as you know, as Ying mentioned in his earlier, that Cardiff Student 5 has completed enrollment last year. So, therefore, that wouldn't be involved with the additional mitigation strategies that we've incorporated. Um, how we will report it, I think remains to be seen, but I think it's clear that it's something that we've incorporated in that study as well as, as you mentioned in our study in gratitude to in the, in that cohort G. so we look forward to presenting some of this data and at the appropriate time this year next year.

And Mitch, I know you asked about the breakouts, right? So. Based on the biomarker data we collected from the nearly 1,000 patient database on CAR2 program, we believe about 20% of patients could potentially reach that threshold and therefore could be benefiting from this ALC monitoring and the dexamethasone prophylaxis treatment.

Thank you.

Our next question comes from Justin Zelen with BTIG. Your line is open.

Great. Thanks for taking the question. This is Jidan for Justin. So you said you expect the majority of patients to ultimately be treated outpatient, but can you share any color on what percent you think can ultimately be treated there? Is there a plateau here on outpatient versus inpatient? And a second question more on the financial side, how should we be thinking about CAPEX going forward from a modeling perspective? Thanks.

Yeah, we're seeing continued growth in the outpatient setting. I don't think there's really a cap that we've modeled in terms of how far that can go. As I said before, centers tend to start with inpatient utilization, and then they very quickly develop the protocol, and it's beneficial for patients and the center. So, that continues to grow. There's no really, you know, ceiling on that.

And also, we continue to invest in our CapEx worldwide. but the bulk of it will be completed in 2025.

Thank you.

Our next question comes from Ash Verma with UBS. Your line is open.

Hi. Thanks for taking my questions. So can you remind us when do you start to see meaningful benefit from the Novartis commercial manufacturing and then what percentage of electricity let's say by the end of this year would be driven off Novartis and then secondly it's encouraging to see this kind of data but how would this play out in the community setting and as you're starting to look to have more of a focus on the outpatient setting would the physicians manage the blood work etc in that setting without any resistance or do you think that might potentially become a hurdle thanks right

Just with the Novartis commercial approval this quarter, we expect that that will start to meaningfully contribute in the second quarter of this year. And I don't think we break down the percentage contribution of our overall capacity. But again, it's an important part of us doubling capacity this year.

Regarding your other question about the exciting tandem data that was presented and how this would be adopted in the community setting, I think it's important to note that ALC is a very typical lab result that is checked very frequently and commonly at all centers, including academic centers as well as in the community setting. So, it's something that's easily applicable even in the outpatient setting. In addition, steroids, a low, short dose of steroids is something that can be done very easily as well. inexpensive and readily available at all of these centers, again, in the academic as well as community setting. Therefore, we think that if this proves to be a very successful risk mitigation strategy, that it would be easily adoptable.

Thank you.

Our next question comes from George Farmer with Scotiabank. Your line is open.

Hi, thanks for taking my questions. Two from me. One, can you talk about meeting demand in Europe a little bit more? You know, we got some feedback from European docs that they've been having a bit of trouble getting demand filled for their patients. That's number one. And then number two, you know, now that you have CART2-5 wrapped up in CART2-6, closing enrollments shortly. How should we think about R&D going forward? Thanks.

So the demand in Europe is being satisfied by our two facilities in Ghent and in part by Raritan, but more and more we're exclusively going to be supplying it from our Ghent facilities. So that's all we'll ask. And that was approved for commercial use in September of 2024. So it really is now at this point coming through the holidays, just now delivering at full capacity. And then as we mentioned, our TechLink facility, which we're continuing to invest in, we anticipate having commercial approval by the end of 2025. So between now and end of 2025, to your point, demand is, we're still in a supply-constrained environment in Europe, and demand is, as demand grows, we're going to work to keep up. There is a queue in the in the Ghent facilities to support the European markets. We are working very closely with each center to make sure that we deliver the product when we can. And overall, across our network, we're increasing reliability, particularly in our Raritan facility, where when we have a projected delivery date, 95% of the time we're able to deliver product on it before that delivery date.

Regarding your R&D spend question, so we remain financially disciplined, and that's why you see a slashed spending in R&D despite significant growth in revenue from Q4-23. And I want to say that next year you may still see similar spending in R&D for BCMA, but then in 2027 you may see declining in the BCMA R&D fund.

Thank you. Our next question comes from Sean McCutcheon with Raymond James. Your line is open.

Hi, guys. Thanks for taking the questions. Can you speak a bit more to how broadly the ALC monitoring and mitigation protocols are being implemented now and how that process of communicating these findings is going across the spectrum of treatment facilities versus how much of a gating factor for their clinical data will be for that process? And then maybe separately for that 2028 Tech Lane expansion, is that part of the current CAPEX initiative? And if not, can you give some more color there?

Thanks.

Thanks for the question. Regarding the implementation of the ALC, I think what's clear is that the tandem results were very intriguing for most and definitely started a lot of conversation on this topic. Talking to investigators, I think a lot of them were looking for potential ways and strategies to mitigate the more notable neurotoxic disease, such as MNTs and Parkinsonism. Therefore, many of the centers that we spoke to were interested in potentially utilizing this mitigation strategy. The NCCN guidelines do suggest looking at ALC as a marker for Part T expansion. And while the tandem data are single centers, we do feel that it opened the conversation and we are investigating actively additional studies, both internally and externally to provide more information on this mitigation strategy moving forward this year. And next year, as we talked about earlier, we have. an investigator-initiated trial that we're having conversations with multiple centers on participating. In addition, we've incorporated the strategy into our internal programs that have ongoing enrollment in the CARTITUDE studies. In addition, there's other real-world evidence data that will be coming out both at conferences as well as manuscripts throughout this year. So, we look forward to interrogating this further and spreading this to more and more centers that we will be talking to further.

Regarding your question on tackling expansion plans, so the phase one will be completed this year, that we will have clinical production in first half, commercial production in the second half, and for phase two, we will invest incremental of $150 million, and that will start in second half of 2025. and we expect to complete in 2028. And early engineering and design work has already been initiated.

Thank you. Our next question comes from Rick Bianchowski with Cantor Fitzgerald. Your line is open.

Hey, good morning, everyone. Congrats on the progress, and thanks for taking the question. So given there is a lot of uncertainty regarding U.S. tariff policy, I wanted to ask about the potential impact on CARVICTI. If broad tariffs are maintained on Canada, Mexico, and China, is there any impact to the manufacturing costs of CARVICTI moving forward or any potential impact to the supply chain?

Hi, Rick. This is Jessie. So under our current assessment, we have immaterial exposure to tariffs in Canada, Mexico, and China. We will continue to monitor the situation closely. And just a reminder regarding your supply chain question, all our potential product comes from the U.S. and Europe, and we plan to supply Europe from our Belgian facilities going forward.

Great. Thank you.

Thank you. Our next question comes from Prim Lockman with Maximus Capital. Your line is open.

Hi, Ying. I'd like to ask you two or three questions. First, can you clarify that the outlook for this year is modest sequential growth in the first quarter following a strong Q4, stronger sequential growth in Q2, as Alan said, and then the second half of the year also will be stronger? Are you comfortable with the consensus $1.9 billion estimate for this year? And secondly, The question regarding 26 outlook that was asked earlier, 10,000 patient run rate, increased penetration in the outpatient setting, like you said, it's over 400,000 per patient. The math is pretty straightforward, but the analyst estimates are lower. The reason is they're expecting a new competitor in the second half of the year. So can you clarify the market dynamics you intend to see versus a new competitor in the second half of the year, and how you're going to maintain your strong 90% market share, or how you're going to maintain your market share strength in the multiple myeloma market. Thanks.

Thank you for the questions. So I'll address the first one. Yes. We feel highly confident about achieving the doubling of the commercial supply. I'm not exactly a consensus number, but as you heard from my colleague, Alan, we feel confident that we can deliver that to the market. And I can also confirm that we do expect sequential growth in Q1 and also the following three quarters, as you correctly mentioned. We do expect significant growth in the second quarter thanks to the Novartis CMO facility coming online and also the continued expansion in Raritan and also our Belgium facilities. We do expect also stronger second half of this year. Again, at this point, we anticipate sequential growth in third quarter and in fourth quarter as well. Regarding our second question, we do see potential competition coming in in the 2026, probably in the second half of 2026. However, you also heard from my colleague, Alan, saying that at this point, we already have over half of our revenue coming from the second to fourth line. And we have seen that in the last three quarters, every single quarter, based on our internal data from the ordering system. we have seen higher market share in second to fourth line compared to the prior quarters. And we do expect that trend to continue for the rest of 2025. So by end of this year, we fully expect that two-thirds or maybe three-quarters of our revenue will come in from second to fourth line. Therefore, we think we're very well positioned to enter into 2026 because by then, the large overwhelming majority of our revenue mix will come in from the second to fourth line. CAR-D4 indication. And as you know, we feel really good about CAR-VICT's profile because its safety and efficacy have been consistently demonstrated from late line to early line trial across different settings in the clinic. And we also have the unmatched PFS CR rate, and now overall survival, which we do expect to be written in the label in the first half in Europe, and then second half in the U.S. approved by FDA. So we think that CARVICT is the best-in-class therapy that is prompted by data and facts. Thank you.

Thank you. That's all the time we have for questions. Thank you for your participation. This does conclude the program, and you may now disconnect. Everyone, have a great day.